Extreme variability of Her-2 expression in gastric cancer[J] . Piera Balzarini,Stefania Manenti,Luisa Benerini Gatta,Vincenzo Villanacci.Digestive and Liver Disease . 2013 (7)Balzarini P, Manenti S, Oatta LB, et al.. Extreme variability of Her-2 expression in gastric cancer[J]. Dig Liver...
Kataoka,Y.,Okabe,etc.HER2 expression and its clinicopathological features in resectable gastric cancer[J].2013,1(1).Yoshiki;Kataoka;Hiroshi;Okabe;Akihiko;Yoshizawa;Sachiko;Minamiguchi;Kenichi;Yoshimura;Hironori;Haga;Yoshiharu;Sakai.HER2 expression and its clinicopathological features in resectable gastric ...
and Ki-67 expressions and the clinicopathological characteristics of gastric cancer. The results showed that the positive and high expression rate of HER2 in gastric cancer was 13.6% (16/118), while the high expression rate of Ki-67 (>30%) was 78.8% (93/118). HER2 expression was ...
HER2 expression and its clinicopathological features in resectable gastric cancer. Gastric Cancer. 2013;16(1):84–93.Kataoka Y, Okabe H, Yoshizawa A, ... Y Kataoka,H Okabe,A Yoshizawa,... - 《Gastric Cancer》 被引量: 99发表: 2013年 [Her2 testing in gastric cancer. What is different in...
Trastuzumab is used to treat HER2-amplified metastatic gastric cancer; however, most patients become trastuzumab-resistant within a year. Knowledge of the mechanisms underlying trastuzumab resistance is required to overcome this limitation. Here, we aimed to elucidate this resistance mechanism using four ...
Chemotherapy and targeted therapy are the major treatments for gastric cancer (GC), but drug resistance limits its effectiveness. Here, we profile the proteome of 206 tumor tissues from patients with GC undergoing either chemotherapy or anti-HER2-based therapy. Proteome-based classification reveals fou...
Conclusion: High expression of CLDN 18.2 in HER-2 positive gastric cancer is associated with poor prognosis, and the optimal treatment mode for this population is worth exploring after the approval of anti-CLDN 18.2 drugs. Keywords: gastric cancer, HER2, claudin 18.2, prognosis Introduction ...
The assessment of human epidermal growth factor receptor 2 (HER2) status in gastric cancer is crucial in selecting patients who may benefit from targeted therapy, yet heterogeneous expression could represent an important drawback for HER2 testing. We aimed to analyze (i) HER2 heterogeneity in primar...
et al. Lnc RNA HOTAIR functions as a competing endogenous RNA to regulate HER2 expression by sponging miR-331-3p in gastric cancer. Mol. Cancer 13, 92 (2014). Article CAS PubMed PubMed Central Google Scholar Xia, T. et al. Long noncoding RNA associated-competing endogenous RNAs in gas...
HER2-positive gastric cancer 来自 万方 喜欢 0 阅读量: 175 作者:Boku,Narikazu 摘要: Human epidermal growth factor receptor 2 (HER2) is involved in the pathogenesis and poor outcomes of several types of cancer, including advanced gastric and gastroesophageal junction cancer. Molecular-targeted drugs,...